Table 2.
Clinicopathologic parameters, 5-year disease-free survival, and 5-year overall survival
| Variable | Total cases | 5-y DFS | 5-y OS | ||
|---|---|---|---|---|---|
| % | p value | % | p value | ||
| 104 | 69% | 75% | |||
| cN stage | 0.48 | 0.32 | |||
| Negative | 52 | 74% | 82% | ||
| Positive | 52 | 65% | 70% | ||
| pN stage | 0.007* | 0.12 | |||
| Negative | 74 | 76% | 78% | ||
| Positive | 30 | 53% | 69% | ||
| Clinical response | 0.02* | 0.18 | |||
| Good response | 54 | 81% | 78% | ||
| Poor response | 50 | 58% | 72% | ||
| TRG | 0.12 | 0.15 | |||
| Good response | 72 | 74% | 79% | ||
| Poor response | 32 | 60% | 68% | ||
| Pre-neoCRT | 104 | ||||
| Tumor PD-L1 | 0.01* | 0.05 | |||
| High | 53 | 84% | 88% | ||
| Low | 51 | 56% | 65% | ||
| Tumor IFN-γ | 0.26 | 0.41 | |||
| High | 44 | 74% | 80% | ||
| Low | 60 | 67% | 71% | ||
| Post-neoCRT | 89 | ||||
| Tumor PD-L1 | 0.008* | 0.0002* | |||
| High | 57 | 81% | 91% | ||
| Low | 32 | 48% | 51% | ||
| NA | 15 | 70% | 67% | ||
| Tumor IFN-γ | 0.47 | 0.36 | |||
| High | 78 | 67% | 75% | ||
| Low | 11 | 82% | 89% | ||
| NA | 15 | 70% | 67% | ||
| pN stage: positive | 30 | ||||
| Tumor PD-L1 (post-neoCRT) | 0.02* | 0.02* | |||
| High | 18 | 69% | 85% | ||
| Low | 12 | 31% | 45% | ||
| pN stage: negative | 74 | ||||
| Tumor PD-L1 (post-neoCRT) | 0.13 | 0.006* | |||
| High | 39 | 87% | 94% | ||
| Low | 20 | 57% | 53% | ||
| NA | 15 | 70% | 67% | ||
Kaplan–Meier method was used for survival analysis. The contrast test did not include the “NA” group. p value was obtained from log-rank test
*p < 0.05
cN stage positive (stage 1 + 2) vs. negative (stage 0), pN stage positive (stage 1a + 1b + 2) vs. negative (stage 0 + X), clinical response good response (complete response and partial response) vs. poor response (stable disease and progressive disease), TRG good response (TRG 3–4) vs. poor response (TRG 1–2), tumor PD-L1 high (grade 2 + 3) vs. low (grade 0 + 1), tumor IFN-γ high (grade 2 + 3) vs. low (grade 0 + 1), SE standard error